BioCanRx-funded Clinical Trials

Important notice for patients: Due to recent circumstances surrounding COVID-19, the clinical trial status listed online may not be accurate. Please contact your cancer care provider (or the specific clinical trial oncologist) to see if the trial you are interested in is recruiting at this time.

To search for a clinical trial, follow these steps:
  1. Click on cancer type.
  2. Click on cancer centre.
  3. Scroll down for information on the clinical trial. Actively recruiting trials will be in green text.
  4. Click to access a lay fact sheet about the trial.
Cancer Type







Cancer Centre










Show Trial Status Legend
Not yet recruiting: The study has not started recruiting participants.
Recruiting: The study is currently recruiting participants.
Enrolling by invitation: The study is selecting its participants from a population, or group of people, decided on by the researchers in advance. These studies are not open to everyone who meets the eligibility criteria but only to people in that particular population, who are specifically invited to participate.
Active, not recruiting: The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.
Suspended: The study has stopped early but may start again.
Terminated: The study has stopped early and will not start again. Participants are no longer being examined or treated.
Completed: The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).
Withdrawn: The study stopped early, before enrolling its first participant.
Unknown: A study on ClinicalTrials.gov whose last known status was recruiting; not yet recruiting; or active, not recruiting but that has passed its completion date, and the status has not been last verified within the past 2 years.
Ontario
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
The Ottawa Hospital (Ottawa, Ontario)
Clinical lead(s): Drs. Derek Jonker, Michael Ong & Guy Ungerechts
Study Number: NCT02879760
Recruitment Status:
Cancer Type(s): Lung Click here for patient information page
A Phase 1/1b, Multicenter, Open-label Trial of Oncolytic MG1 Expressing Mutant Human Papilloma Virus (HPV) E6 and E7 (MG1-E6E7), with Adenovirus Vaccine Expressing Mutant HPV E6 and E7 (AdE6E7) and Atezolizumab in Patients with HPV Associated Cancers (Kingfisher)
The Ottawa Hospital (Ottawa, Ontario)
Clinical lead(s): Drs. Guy Ungerechts, John Bell, Caroline Breitbach, Chantal Lemay
Study Number: NCT03618953
Recruitment Status:
Cancer Type(s): HPV-associated tumours Click here for patient information page
Interrogation of Biomarkers in Patient Samples from a Phase Ib Trial of the Immune Checkpoint Inhibitor, Avelumab, in Combination with SMAC Mimetic Debio1143
The Ottawa Hospital (Ottawa, Ontario)
Clinical lead(s): Drs. Glenwood Goss, Robert Korneluk, Bryan Lo, Harmanjatinder Sekhon
Study Number: NCT03270176
Recruitment Status:
Cancer Type(s): Solid malignancies Click here for patient information page
Canadian-Led Immunotherapies in Cancer: CLIC-1901 for the Treatment of Patients with Relapsed/Refractory CD19 Positive Hematologic Malignancies
The Ottawa Hospital (Ottawa, Ontario)
Clinical lead(s): Drs. Natasha Kekre, John Bell, Dean Fergusson
Study Number: NCT03765177
Recruitment Status:
Cancer Type(s): Blood Click here for patient information page
Phase I clinical trial of Anti-Minor Histocompatibility Antigen Immunotherapy Broadening the Scope of Application for Precision Therapeutics (GLIDE)
The Ottawa Hospital (Ottawa, Ontario)
Clinical lead(s): Drs. Silvy Lachance, Jean-Sébastien Delisle, Denis-Claude Roy
Study Number: NCT03091933
Recruitment Status: Suspended
Cancer Type(s): Hematologic Click here for patient information page
Test the oncolytic vaccine approach in combination with checkpoint inhibitor antibodies
Princess Margaret Cancer Centre (Toronto, Ontario)
Clinical lead(s): Dr. Natasha Leigh
Study Number: NCT02879760
Recruitment Status:
Cancer Type(s): Lung Click here for patient information page
A Phase I Study Evaluating the Feasibility and Safety of Infusion of "Re-Stimulated" Autologous Tumour-Infiltrating Lymphocytes (TILs) Followed by Low-Dose Interleukin-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Princess Margaret Cancer Centre (Toronto, Ontario)
Clinical lead(s): Drs. Marcus Butler
Study Number: NCT01883297
Recruitment Status:
Cancer Type(s): Ovarian Click here for patient information page
Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering Expression of IL-12
Princess Margaret Cancer Centre (Toronto, Ontario)
Clinical lead(s): Drs. Mark Minden & Anna Porwit
Study Number: NCT02483312
Recruitment Status:
Cancer Type(s): AML Click here for patient information page
A Phase 1/1b, Multicenter, Open-label Trial of Oncolytic MG1 Expressing Mutant Human Papilloma Virus (HPV) E6 and E7 (MG1-E6E7), with Adenovirus Vaccine Expressing Mutant HPV E6 and E7 (AdE6E7) and Atezolizumab in Patients with HPV Associated Cancers (Kingfisher)
Princess Margaret Cancer Centre (Toronto, Ontario)
Clinical lead(s): Dr. Amit Oza
Study Number: NCT03618953
Recruitment Status:
Cancer Type(s): HPV-associated tumours Click here for patient information page
Phase Ib trial of pembrolizumab administered following adoptive cell therapy- A multiple cohort study; The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
Princess Margaret Cancer Centre (Toronto, Ontario)
Clinical lead(s): Drs. Marcus Butler, Anna Spreafico, Aaron Hansen
Study Number: NCT03158935
Recruitment Status:
Cancer Type(s): Melanoma and Ovarian Click here for patient information page
Phase Ib trial of pembrolizumab administered following adoptive cell therapy- A multiple cohort study; The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
Princess Margaret Cancer Centre (Toronto, Ontario)
Clinical lead(s): Drs. Marcus Butler, Anna Spreafico, Aaron Hansen
Study Number: NCT03158935
Recruitment Status:
Cancer Type(s): Melanoma and Ovarian Click here for patient information page
Evaluating adoptive cell therapy to treat ovarian cancer using TILs conditioned with dendritic cells
Princess Margaret Cancer Centre (Toronto, Ontario)
Recruitment Status: Not recruiting (Closed)
Cancer Type(s): Ovarian Click here for patient information page
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
Juravinski Cancer Centre (Hamilton, Ontario)
Clinical lead(s): Dr. Sebastien Hotte
Study Number: NCT02879760
Recruitment Status:
Cancer Type(s): Lung Click here for patient information page
A Phase 1/1b, Multicenter, Open-label Trial of Oncolytic MG1 Expressing Mutant Human Papilloma Virus (HPV) E6 and E7 (MG1-E6E7), with Adenovirus Vaccine Expressing Mutant HPV E6 and E7 (AdE6E7) and Atezolizumab in Patients with HPV Associated Cancers (Kingfisher)
Juravinski Cancer Centre (Hamilton, Ontario)
Clinical lead(s): Drs. Brian Lichty, Jonathan Bramson, Hal Hirte, Sebastien Hotte, Gregory Pond
Study Number: NCT03618953
Recruitment Status:
Cancer Type(s): HPV-associated tumours Click here for patient information page
Interrogation of Biomarkers in Patient Samples from a Phase Ib Trial of the Immune Checkpoint Inhibitor, Avelumab, in Combination with SMAC Mimetic Debio1143
Juravinski Cancer Centre (Hamilton, Ontario)
Clinical lead(s): Drs. Jonathan Bramson, Rosalyn Juergens
Study Number: NCT03270176
Recruitment Status:
Cancer Type(s): Solid malignancies Click here for patient information page
Phase I clinical trial of Anti-Minor Histocompatibility Antigen Immunotherapy Broadening the Scope of Application for Precision Therapeutics (GLIDE)
Juravinski Cancer Centre (Hamilton, Ontario)
Clinical lead(s): Drs. Silvy Lachance, Jean-Sébastien Delisle, Denis-Claude Roy
Study Number: NCT03091933
Recruitment Status: Suspended
Cancer Type(s): Hematologic Click here for patient information page
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
Kingston General Hospital (Kingston, Ontario)
Clinical lead(s): Dr. Andrew Robinson
Study Number: NCT02879760
Recruitment Status:
Cancer Type(s): Lung Click here for patient information page
British Columbia
Interrogation of Biomarkers in Patient Samples from a Phase Ib Trial of the Immune Checkpoint Inhibitor, Avelumab, in Combination with SMAC Mimetic Debio1143
BC Cancer Agency (Vancouver, British Columbia)
Clinical lead(s): Drs. Robert Holt, Brad Nelson, Janessa Laskin, Daniel Renouf
Study Number: NCT03270176
Recruitment Status:
Cancer Type(s): Solid malignancies Click here for patient information page
Canadian-Led Immunotherapies in Cancer: CLIC-1901 for the Treatment of Patients with Relapsed/Refractory CD19 Positive Hematologic Malignancies
Vancouver General Hospital (Vancouver, British Columbia)
Clinical lead(s): Drs. Natasha Kekre, John Bell, Dean Fergusson
Study Number: NCT03765177
Recruitment Status:
Cancer Type(s): Blood Click here for patient information page
Quebec
Phase I clinical trial of Anti-Minor Histocompatibility Antigen Immunotherapy Broadening the Scope of Application for Precision Therapeutics (GLIDE)
Maisonneuve-Rosemont Hospital (Montreal, Quebec)
Clinical lead(s): Drs. Silvy Lachance, Jean-Sébastien Delisle, Denis-Claude Roy
Study Number: NCT03091933
Recruitment Status: Suspended
Cancer Type(s): Hematologic Click here for patient information page
New Brunswick
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
The Moncton Hospital (Moncton, New Brunswick)
Clinical lead(s): Dr. Mrudula Avileli
Study Number: NCT02879760
Recruitment Status:
Cancer Type(s): Lung Click here for patient information page
Alberta
Interrogation of Biomarkers in Patient Samples from a Phase Ib Trial of the Immune Checkpoint Inhibitor, Avelumab, in Combination with SMAC Mimetic Debio1143
Cross Cancer Institute (Edmonton, Ontario)
Clinical lead(s): Dr. Quincy Chu
Study Number: NCT03270176
Recruitment Status:
Cancer Type(s): Solid malignancies Click here for patient information page
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
Tom Baker Cancer Centre (Calgary, Alberta)
Clinical lead(s): Dr. Don Morris
Study Number: NCT02879760
Recruitment Status:
Cancer Type(s): Lung Click here for patient information page